A5087530499- Renal and related cancers
- Renal cell carcinoma treatment
- Ethics and Legal Issues in Pediatric Healthcare
- Childhood Cancer Survivors' Quality of Life
- Prenatal Screening and Diagnostics
- Genetic Syndromes and Imprinting
- Epigenetics and DNA Methylation
- Tumors and Oncological Cases
- Urological Disorders and Treatments
- Pancreatic and Hepatic Oncology Research
- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Cancer-related gene regulation
- Complementary and Alternative Medicine Studies
- Cancer Genomics and Diagnostics
- Genetic and Kidney Cyst Diseases
- Sarcoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Congenital Anomalies and Fetal Surgery
- Pediatric Urology and Nephrology Studies
- Pediatric Pain Management Techniques
- Genital Health and Disease
- Digestive system and related health
- Gestational Trophoblastic Disease Studies
- Hedgehog Signaling Pathway Studies
University of Alberta
2016-2025
Stollery Children's Hospital
2005-2023
University of Alberta Hospital
1996-2023
Cancer Institute (WIA)
2002-2023
Alberta Hospital Edmonton
2021-2023
Alberta Children's Hospital
2017-2022
University Hospital Southampton NHS Foundation Trust
2021
Essex Cardiothoracic Centre
2021
Rabin Medical Center
2019
St. Jude Children's Research Hospital
2006-2018
To determine if tumor-specific loss of heterozygosity (LOH) for chromosomes 1p or 16q is associated with a poorer prognosis children favorable-histology (FH) Wilms tumor entered on the fifth National Tumor Study (NWTS-5).Between August 1995 and June 2002, 2,021 previously untreated FH anaplastic tumor, clear-cell sarcoma kidney (CCSK) malignant rhabdoid (RTK), were treated stage- histology-specific therapy. Their tumors assayed LOH polymorphic DNA markers 16q. ResultsLOH was rarely observed...
An objective of the fifth National Wilms' Tumor Study (NWTS-5) was to evaluate efficacy treatment regimens for anaplastic histology tumor (AH).Prospective single-arm studies were conducted. Patients with stage I AH treated vincristine and dactinomycin 18 weeks. stages II IV diffuse vincristine, doxorubicin, cyclophosphamide, etoposide 24 weeks plus flank/abdominal radiation.A total 2,596 patients enrolled onto NWTS-5, whom 281 (10.8%) had AH. Four-year event-free survival (EFS) overall (OS)...
PURPOSE The National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of administration different regimens for treatment tumor (WT). PATIENTS AND METHODS Between August 6, 1986 September 1, 1994, 1,687 previously untreated children less than 16 years age with stages I II/favorable histology (FH) or stage I/anaplastic WT (low-risk [LR] group) III IV/FH IV/clear cell sarcoma kidney (high-risk [HR] were randomized that included vincristine either...
Parental origin-specific alterations of chromosome 11p15 in human cancer suggest the involvement one or more maternally expressed imprinted genes involved embryonal tumor suppression and cancer-predisposing Beckwith-Wiedemann syndrome (BWS). The gene encoding cyclin-dependent kinase inhibitor p57KIP2, whose overexpression causes G1 phase arrest, was recently cloned mapped to this band. We find that p57KIP2 is imprinted, with preferential expression maternal allele. However, imprint not...
The characteristics of 367 stage I-IV National Wilms' Tumor Study (NWTS) children who relapsed after initial treatment for unilateral disease in the second and third NWTS trials (NWTS-2 -3) were analyzed to identify features predictive survival. Although modifications therapy resulted a lower rate first relapse these two studies compared with NWTS-1, all previously identified prognostic factors remained statistically significant predictors histology, length remission, v three drugs, site...
PURPOSE To evaluate the effect of combination vincristine, dactinomycin, and doxorubicin with (regimen J) or without DD-RT) cyclophosphamide on relapse-free survival children stages II to IV Wilms' tumor focal diffuse anaplasia. PATIENTS AND METHODS We reviewed clinical courses all randomized patients from National Tumor Study (NWTS)-3 NWTS-4 anaplastic tumor, determined 4-year rate separately for those Anaplasia was evaluated using newly developed topographic definitions RESULTS The five...
We evaluated the use of alternating cycles cyclophosphamide/etoposide and carboplatin/etoposide in children entered on National Wilms Tumor Study (NWTS)-5 who were diagnosed between August 1, 1995 May 31, 2002 relapsed after chemotherapy with vincristine, actinomycin D, doxorubicin (VAD) radiation therapy (DD-4A).One hundred three patients or had progressive disease initial VAD registered stratum C NWTS-5 Relapse protocol. Twelve not evaluable: five due to insufficient data, six major...
Abstract Background To review the clinical characteristics and survival of infants diagnosed with a primary renal tumor in first 7 months life. Procedure A retrospective data patients registered five large international protocols (SFOP/GPOH/SIOP9/93‐01, UKW3 NWTSG 4 5) spanning 1985–2002. Results 750 (7.2%) 10,430 were before age 213 days. Tumor types Wilms (WT) 58%; congenital mesoblastic nephroma (CMN) 18%; malignant rhabdoid (MRTK) 8%; clear cell sarcoma (CCSK) 2%; non‐Wilms (unspecified)...
Wilms tumour (WT) is an embryonal kidney neoplasia for which very few driver genes have been identified. Here we identify DROSHA mutations in 12% of WT samples (26/222) using whole-exome sequencing and targeted 10 microRNA (miRNA)-processing genes. A recurrent mutation (E1147K) affecting a metal-binding residue the RNase IIIb domain detected 81% DROSHA-mutated tumours. In addition, non-recurrent other this pathway (DGCR8, DICER1, XPO5 TARBP2). By assessing miRNA expression pattern...
Purpose The goal of this study was to analyze the association copy number gain 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall (OS) within each tumor stage 1p 16q loss and/or heterozygosity. Methods Unilateral FHWTs from 1,114 patients enrolled National Tumor Study-5 that were informative for microsatellite markers (previously determined) gain, loss, using multiplex ligation-dependent probe amplification analyzed. Results Eight-year EFS 86% (95% CI,...
The Children's Oncology Group study AREN0534 aimed to improve event-free survival (EFS) and overall (OS) while preserving renal tissue by intensifying preoperative chemotherapy, completing definitive surgery 12 weeks from diagnosis, modifying postoperative chemotherapy based on histologic response.
Wilms tumors (WT) have provided broad insights into the interface between development and tumorigenesis. Further understanding is confounded by their genetic, histologic, clinical heterogeneity, basis of which remains largely unknown. We evaluated 224 WT for global gene expression patterns; WT1, CTNNB1, WTX mutation; 11p15 copy number methylation patterns. Five subsets were identified showing distinct differences in pathologic features: these findings validated 100 additional WT. The pattern...
Purpose The National Wilms Tumor Study (NWTS) treatment of favorable histology tumor with lung metastases was vincristine/dactinomycin/doxorubicin (DD4A) and radiation therapy (RT). AREN0533 study applied a new risk stratification strategy to improve event-free survival (EFS) while reducing exposure RT. Methods Patients isolated showing complete nodule response (CR) after 6 weeks DD4A continued receiving chemotherapy without incomplete (IR) or loss heterozygosity at chromosomes 1p/16q...
Purpose The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether mutational status confers additional prognostic information. Patients Methods We studied 40 DAWT the tissue from which DNA was extracted analysed for 17p loss. majority cases were profiled by copy number (n = 32) gene expression 36) arrays. correlated patient event-free overall survival, genomic...
Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) radiation therapy. Further risk stratification required improve outcomes reduce late effects. We evaluated clinical biologic variables for patients with FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p 16q treated in the Children’s Oncology Group protocol AREN0532. Methods From October 2006 August...